THNR
THNR 1-star rating from Upturn Advisory

Amplify Weight Loss Drug & Treatment ETF (THNR)

Amplify Weight Loss Drug & Treatment ETF
 (THNR) 1-star rating from Upturn Advisory
$26.08
Last Close (24-hour delay)
Profit since last BUY4.78%
upturn advisory logo
Consider higher Upturn Star rating
BUY since 29 days
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/24/2025: THNR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type ETF
Historic Profit -7.59%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/24/2025

Key Highlights

Volume (30-day avg) -
Beta -
52 Weeks Range 18.56 - 27.93
Updated Date 06/30/2025
52 Weeks Range 18.56 - 27.93
Updated Date 06/30/2025

About Amplify ETF Trust

Exchange NYSE ARCA
Headquaters -
IPO Launch date -
CEO -
Sector -
Industry -
Full time employees -
Website
Full time employees -
Website

The fund's manager invests at least 80% of its net assets (plus borrowings for investment purposes) in securities that comprise the index. The index is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business or who enable such business. GLP-1 agonists seek to lower blood sugar levels and reduce appetite and promote fullness, with the ultimate potential for weight loss. The fund is non-diversified.